Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that it enclosed its Press Release relating to ‘Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma’. 

The above information is a part of company’s filings submitted to BSE.